Quick Dispatch:
Your tirzepatide cardiovascular outcomes trial results august 2025 Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your tirzepatide cardiovascular outcomes trial results august 2025 Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity ships.
Need Help?
Questions about tirzepatide cardiovascular outcomes trial results august 2025 Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for tirzepatide cardiovascular outcomes trial results august 2025 Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity in your area.
Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes
20.42
In patients with type 2 diabetes and atherosclerotic cardiovascular disease, tirzepatide was noninferior to dulaglutide with respect to major cardiovascular events. , , Read the full SURPASS-CVOT
27.20
Tirzepatide and the 10‐year predicted risk of cardiovascular disease and type 2 diabetes in adults with obesity and prediabetes: A post hoc analysis from the three‐year SURMOUNT‐1 trial - Hankosky
21.71
Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis
20.53
In the SURPASS-CVOT head-to-head trial involving over 13,000 adults with T2D and ASCVD, tirzepatide (Mounjaro) matched dulaglutide in reducing major cardiovascular events (8% lower risk) and significantly cut all-cause mortality by 16%
27.83
Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity
25.55
Tirzepatide and the 10‐year predicted risk of cardiovascular disease and type 2 diabetes in adults with obesity and prediabetes: A post hoc analysis from the three‐year SURMOUNT‐1 trial - Hankosky
29.46
